
Today's positive results from Ambu's clinical study with its new and improved duodenoscope product, the Ascope Duodeno 1.5, have been received well by investors, who have sent Ambu's share price up, as observed by Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
On Monday morning, Ambu shares have increased in price by 5.4 percent to total DKK 200.1 (USD 30,4) on the stock exchange in Copenhagen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app